Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

Authors

Keywords

Journal

Volume 3, Issue -, Pages 254-258

Publisher

Termedia Sp. z.o.o.

Online

2017-11-14

DOI

10.5114/wo.2017.70116

Explore over 38,000 international journals covering a vast array of academic fields.

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now